Truist Securities Rates Guardian Pharmacy Services (GRDN) buy

Analyst David Macdonald reaffirmed a buy rating on Guardian Pharmacy Services with a $47.00 target as the stock trades below recent highs, a 19.93% upside from the current price.

By EarningsIQ Research Desk · Published Jun 18, 2026, 3:02 AM EDT · Updated Jun 24, 2026, 6:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Truist Securities rated Guardian Pharmacy Services, Inc. ($GRDN) "buy" with a $47 price target on June 17, 2026.

Since the rating, $GRDN is down 11.7% after 1 week, down 6.6% after 1 month and down 9.1% to date (from the $43.40 close on Jun 17, 2026).

GRDN Guardian Pharmacy Services, Inc.

$39.47 +33.66% year to date

Daily close · Oct 16, 2026

Key Points

Truist Securities analyst David Macdonald reiterated a buy rating on Guardian Pharmacy Services (NYSE: GRDN) with a $47.00 target on June 17, 2026.
Truist Securities's $47 price target implies 19.93% upside from Guardian Pharmacy Services, Inc.'s ($GRDN) current $39.19 share price.
Shares of Guardian Pharmacy Services trade near $39.19, sitting below the 50-day moving average of $40.57 and a 52-week high of $48.33.
Other Wall Street firms covering the stock include Keybanc and Oppenheimer, contributing to an overall consensus strong buy rating.

Get $GRDN trade alerts by text

We text you when insiders, Congress or big funds trade $GRDN. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Guardian Pharmacy Services, Inc. alert may contain errors. Disclosures

Truist Securities Stays Bullish on Guardian Pharmacy Services

Truist Securities analyst David Macdonald reaffirmed a buy rating on Guardian Pharmacy Services, Inc. (NYSE: GRDN) on June 17, 2026, setting a target price of $47.00. The update provides insight into where the firm sees valuation headroom as the equity moves through the middle months of the year. With shares changing hands around $39.19, the target points to notable room for upward movement compared to the current market price.

Stock Valuation and Trading Levels

The equity trades near $39.19, positioned just under its 50-day moving average of $40.57 and well above its 200-day moving average of $36.58. Over the past year, the shares have moved between a low of $23.14 and a high of $48.33. The company carries a market capitalisation of roughly $2.80 billion, paired with a trailing price-to-earnings ratio of 42.46 and a forward price-to-earnings ratio of 30.88.

12-month forecast

$GRDN price target

Guardian Pharmacy Services, Inc. daily closes and this analyst's $47 target. Not advice.

Wall Street Coverage and Firm Updates

Other financial institutions have also adjusted their outlooks on the pharmacy services provider in recent months. On September 23, 2026, Keybanc initiated coverage with an overweight rating and a $52.00 price target. Earlier on September 21, 2026, Truist Securities maintained its buy rating while adjusting its price target to $51.00. Before that, on August 7, 2026, Oppenheimer kept an outperform rating while raising its target to $49.00 from $43.00. Across the broader analyst community, the stock holds a consensus recommendation key of strong buy with a target mean price of $49.50 based on six analyst opinions, with targets spanning from a low of $47.00 to a high of $51.00.

Providing Technology and Support to Care Facilities

Guardian Pharmacy Services, Inc. operates in the healthcare sector, providing specialized technology-enabled pharmacy services to residents of long-term care facilities across the United States. Its clinical capabilities and proprietary tools help local pharmacies and care facilities manage medication spending and patient care safely. Market participants watch these operational updates closely as management prepares for the next financial results release.

What to Watch Next for Guardian Pharmacy Services

Investors are watching for the company's next financial results, which are scheduled for release on November 9, 2026. Those upcoming disclosures will provide fresh figures on revenue growth and profit margins, helping the market gauge whether current valuation multiples align with actual business expansion.